vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Pioneer Bancorp, Inc. (PBFS). Click either name above to swap in a different company.

Pioneer Bancorp, Inc. is the larger business by last-quarter revenue ($25.0M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). Pioneer Bancorp, Inc. runs the higher net margin — 82.1% vs -177.4%, a 259.5% gap on every dollar of revenue. Over the past eight quarters, Pioneer Bancorp, Inc.'s revenue compounded faster (144.9% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Pioneer Bancorp, Inc. (MD) is a bank holding company operating as the parent entity of Pioneer Bank. It provides a full suite of retail and commercial banking products and services, including deposit accounts, residential and commercial mortgages, consumer loans, and small business financing, primarily serving individual and corporate customers across local communities in Maryland, U.S.

LAB vs PBFS — Head-to-Head

Bigger by revenue
PBFS
PBFS
1.3× larger
PBFS
$25.0M
$19.6M
LAB
Higher net margin
PBFS
PBFS
259.5% more per $
PBFS
82.1%
-177.4%
LAB
Faster 2-yr revenue CAGR
PBFS
PBFS
Annualised
PBFS
144.9%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
PBFS
PBFS
Revenue
$19.6M
$25.0M
Net Profit
$-34.7M
$3.7M
Gross Margin
48.5%
Operating Margin
-168.5%
21.3%
Net Margin
-177.4%
82.1%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
PBFS
PBFS
Q4 25
$25.0M
Q3 25
$19.6M
$24.0M
Q2 25
$21.8M
$24.4M
Q1 25
$40.8M
$22.8M
Q3 24
$22.1M
$22.0M
Q2 24
$22.5M
$20.9M
Q1 24
$45.5M
$21.6M
Q4 23
$28.2M
$4.2M
Net Profit
LAB
LAB
PBFS
PBFS
Q4 25
$3.7M
Q3 25
$-34.7M
$4.3M
Q2 25
$-33.5M
$6.5M
Q1 25
$-26.0M
$5.8M
Q3 24
$-26.9M
$6.3M
Q2 24
$-45.7M
$3.9M
Q1 24
$-32.2M
$4.7M
Q4 23
$-19.8M
$3.2M
Gross Margin
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Operating Margin
LAB
LAB
PBFS
PBFS
Q4 25
21.3%
Q3 25
-168.5%
23.4%
Q2 25
-118.1%
33.3%
Q1 25
-80.8%
32.5%
Q3 24
-120.9%
37.2%
Q2 24
-134.5%
24.1%
Q1 24
-132.2%
28.1%
Q4 23
-75.9%
96.1%
Net Margin
LAB
LAB
PBFS
PBFS
Q4 25
82.1%
Q3 25
-177.4%
18.0%
Q2 25
-153.7%
26.4%
Q1 25
-63.8%
25.3%
Q3 24
-122.0%
28.7%
Q2 24
-203.3%
107.4%
Q1 24
-70.6%
21.9%
Q4 23
-70.2%
76.4%
EPS (diluted)
LAB
LAB
PBFS
PBFS
Q4 25
$0.16
Q3 25
$-0.09
$0.18
Q2 25
$-0.09
$0.26
Q1 25
$-0.07
$0.23
Q3 24
$-0.07
$0.25
Q2 24
$-0.12
$0.15
Q1 24
$-0.27
$0.19
Q4 23
$-0.24
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
PBFS
PBFS
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$323.9M
Total Assets
$539.6M
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Total Debt
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Stockholders' Equity
LAB
LAB
PBFS
PBFS
Q4 25
$323.9M
Q3 25
$399.7M
$314.2M
Q2 25
$424.5M
$314.2M
Q1 25
$454.6M
$310.7M
Q3 24
$489.3M
$303.8M
Q2 24
$510.3M
$296.5M
Q1 24
$577.3M
$289.0M
Q4 23
$-148.1M
$283.8M
Total Assets
LAB
LAB
PBFS
PBFS
Q4 25
$2.2B
Q3 25
$539.6M
$2.2B
Q2 25
$557.0M
$2.1B
Q1 25
$579.6M
$2.1B
Q3 24
$681.5M
$2.0B
Q2 24
$708.7M
Q1 24
$777.7M
$2.0B
Q4 23
$323.1M
$1.9B
Debt / Equity
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
PBFS
PBFS
Operating Cash FlowLast quarter
$-22.2M
$11.1M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
2.97×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
PBFS
PBFS
Q4 25
$11.1M
Q3 25
$-22.2M
$3.9M
Q2 25
$-20.7M
$5.1M
Q1 25
$-30.3M
$-3.5M
Q3 24
$-27.9M
$1.9M
Q2 24
$-39.0M
$9.0M
Q1 24
$-62.5M
$3.3M
Q4 23
$-14.1M
$-943.0K
Free Cash Flow
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
FCF Margin
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Capex Intensity
LAB
LAB
PBFS
PBFS
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Cash Conversion
LAB
LAB
PBFS
PBFS
Q4 25
2.97×
Q3 25
0.90×
Q2 25
0.78×
Q1 25
-0.61×
Q3 24
0.30×
Q2 24
2.30×
Q1 24
0.70×
Q4 23
-0.30×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

PBFS
PBFS

Segment breakdown not available.

Related Comparisons